Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Lynparza | olaparib | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ultomiris | ravulizumab | AChR antibody-positive generalized Myasthenia Gravis | Do not reimburse | Complete | ||
| N/A | bevacizumab and lomustine | Recurrent glioblastoma multiform | Reimburse with clinical criteria and/or conditions | Complete | ||
| Sotyktu | deucravacitinib | Psoriasis, moderate to severe plaque | Do not reimburse | Complete | ||
| Zoryve | roflumilast | Plaque psoriasis | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | dapagliflozin | Chronic kidney disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Korsuva | difelikefalin | Chronic kidney disease | Do not reimburse | Complete | ||
| Vraylar | cariprazine | Schizophrenia | Do not reimburse | Complete | ||
| Lynparza | olaparib | gBRCAm, HER2-negative high-risk early breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Pluvicto | lutetium vipivotide tetraxetan | Metastatic castration-resistant prostate cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 10, 2024